Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) - Cash Flow Conversion Efficiency

Latest as of June 2023: -0.010x

Based on the latest financial reports, Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) has a cash flow conversion efficiency ratio of -0.010x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-64.53 Million ≈ $-75.45 Million USD) by net assets (€6.39 Billion ≈ $7.47 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Review how financially flexible is Tianjin Zhong Xin Pharmaceutical Group C to assess the company's free cash flow relative to its total liabilities.

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see Tianjin Zhong Xin Pharmaceutical Group C stock valuation for the company's overall valuation and market capitalisation.

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Zhang Xiaoquan Inc. SHE:301055	N/A
MD Pictures Tbk PT JK:FILM	-0.012x
Runner Xiamen Corp SHG:603408	0.071x
Wecome Intelligent Manufacturing Co. Ltd. SHG:603070	N/A
China Bills Finance Corp TW:2820	0.027x
SLR Investment Corp NASDAQ:SLRC	0.049x
Shandong Weida Machinery Co Ltd SHE:002026	0.025x
Getein Biotech Inc SHG:603387	0.034x

Annual Cash Flow Conversion Efficiency for Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2013–2025)

The table below shows the annual cash flow conversion efficiency of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited from 2013 to 2025. View Tianjin Zhong Xin Pharmaceutical Group C stock price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€7.10 Billion ≈ $8.30 Billion	€461.07 Million ≈ $539.03 Million	0.065x	-44.87%
2024-12-31	€7.85 Billion ≈ $9.18 Billion	€924.67 Million ≈ $1.08 Billion	0.118x	+13.69%
2023-12-31	€6.65 Billion ≈ $7.77 Billion	€688.49 Million ≈ $804.91 Million	0.104x	+0.23%
2022-12-31	€6.55 Billion ≈ $7.66 Billion	€677.25 Million ≈ $791.77 Million	0.103x	-21.01%
2021-12-31	€6.51 Billion ≈ $7.62 Billion	€852.40 Million ≈ $996.55 Million	0.131x	+15.96%
2020-12-31	€5.95 Billion ≈ $6.96 Billion	€671.42 Million ≈ $784.96 Million	0.113x	+25.79%
2019-12-31	€5.52 Billion ≈ $6.46 Billion	€495.49 Million ≈ $579.28 Million	0.090x	+29.50%
2018-12-31	€5.05 Billion ≈ $5.91 Billion	€350.14 Million ≈ $409.36 Million	0.069x	+8165.98%
2017-12-31	€4.63 Billion ≈ $5.41 Billion	€-3.97 Million ≈ $-4.64 Million	-0.001x	-100.88%
2016-12-31	€4.30 Billion ≈ $5.03 Billion	€417.77 Million ≈ $488.42 Million	0.097x	+10.55%
2015-12-31	€4.11 Billion ≈ $4.80 Billion	€360.58 Million ≈ $421.56 Million	0.088x	-9.77%
2014-12-31	€2.95 Billion ≈ $3.44 Billion	€286.85 Million ≈ $335.36 Million	0.097x	+17.45%
2013-12-31	€2.57 Billion ≈ $3.01 Billion	€213.44 Million ≈ $249.53 Million	0.083x	--

About Tianjin Zhong Xin Pharmaceutical Group Corporation Limited

STU:2TZ Germany Drug Manufacturers - Specialty & Generic

Market Cap

$692.11 Million

€592.00 Million EUR

Market Cap Rank

#10662 Global

#1244 in Germany

Share Price

€2.96

Change (1 day)

+8.82%

52-Week Range

€2.11 - €3.15

All Time High

€3.15